Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%) Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024 Operational improvements ...

Fredrik Brag, CEO and Founder of Median Technologies, commented: "The past quarter has seen the successful culmination of a transformational period for the Company: we are beginning to see the ...

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses ...

Median Technologies eyonis lung cancer screening (LCS) diagnostic has met the primary endpoint in a second pivotal study ...

Median Technologies has secured up to €47.5m ($49.9m) to support the regulatory filing and commercialisation efforts for its ...

Last month, Median said that it was preparing to file for FDA approval of iBiopsy for lung cancer screening, aiming at a green light for the SaMD before the end of 2023, based on study data ...

About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses ...

Median Technologies informs its shareholders and the financial community that its annual financial report on the accounts for the year ended December 31, 2024, has been made available and filed ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company ...

iCRO will continue to increase its profitability, the increase of the order backlog will drive future growth. Median Technologies informs its shareholders and the financial community that its annual ...

Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%) Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024 Operational improvements ...